Parental Stimulant Medication Added to Parental Behavioral Therapy Led to Better Outcomes for Parent-and-Child Pairs With ADHD 

 ADHD in the News 2026-09-24


[Excerpt] A team at the University of Maryland, College Park, led by Dr. Andrea Chronis-Tuscano, recently reported results of a trial that took 6 years to complete, involving parent-child dyads, or pairs, with ADHD. The objective was to determine if treating ADHD parents with both an ADHD medication and an evidence-based behavioral parenting intervention (called I-BPT) designed to improve parenting skills relevant in caring for young children with ADHD would improve outcomes among the children—compared with outcomes in children whose parents received the parenting intervention alone, without medication.

View Article: Brain & Behavior Research Foundation, September 24, 2026




Other Articles in this Edition

Tylenol during pregnancy not linked to autism, ADHD, major review finds 

Padilla, Murphy Introduce Bill to Protect Students from Physical Abuse, End Dangerous Corporal Punishment Practices in Schools

Peer Exchange: Managing Adult ADHD: Addressing Diagnosis, Treatment Selection, and All-Day Symptom Control, EP. 3 & 4 (Opinion)

Adult ADHD: Does Age at Diagnosis Affect Clinical Profile?

Parental Stimulant Medication Added to Parental Behavioral Therapy Led to Better Outcomes for Parent-and-Child Pairs With ADHD 

Navigating roadblocks to autism, ADHD diagnoses for Hispanic families 

Air Force Tech Specialist Faces Potential Discharge Over a Prescribed ADHD Medication 

New Consensus Recommendations for Comprehensive ADHD Monitoring 

Methylphenidate and Lisdexamfetamine Show Comparable Risk for Abuse 

Menstrual Symptoms Linked to Depression, ADHD, and Anxiety in Adolescent Girls 

Meta-analysis Finds Long-term Exercise Associated with Moderate Improvements in Executive Functioning for Children and Adolescents with ADHD 

Children’s pupils may reveal shifting attention in ADHD, especially when off medication

People with similar mental health conditions tend to end up together, raising risk within families 

With pioneering ADHD data, Alkermes eyes orexin agonist as potential ‘company changer’